Sun Pharma reported strong FY26 results with consolidated revenue up 11.9% to ₹58,462 crore and net profit at ₹11,479 crore. The company also announced a strategic acquisition of Organon & Co for US$11.75 billion, aiming to expand its global scale and enter the Women's Health segment.
Sun Pharma Reports Robust FY26 Performance Amid Strategic Acquisition
Sun Pharma's consolidated revenue for FY26 reached ₹58,462 crore, marking an 11.9% increase year-on-year. Net profit after minority interest stood at ₹11,479 crore. Research and Development (R&D) expenditure was ₹3,554 crore, equivalent to 6.1% of sales, while earnings per share (EPS) was ₹47.8.
Reader Takeaway: Strong revenue growth and innovative pivot; US regulatory pressures remain a watchpoint.
What just happened
Sun Pharmaceutical Industries Ltd. announced its financial results for the fiscal year ending March 2026 (FY26). The company reported significant growth in its consolidated revenue and net profit. A major announcement was the definitive agreement to acquire Organon & Co. for an enterprise valuation of US$11.75 billion. This strategic acquisition aims to enhance Sun Pharma's global presence, introduce Women's Health as a new core therapeutic area, and bolster its biosimilars business.
Why this matters
The strong financial performance indicates healthy demand across Sun Pharma's key markets. The proposed acquisition of Organon & Co. represents a significant strategic shift, potentially transforming the company's product portfolio and geographic reach. For investors, this signals a move towards higher-value segments and global expansion, though integration challenges and existing regulatory concerns need careful monitoring.
The backstory
Sun Pharma has been focusing on growing its innovative medicines business, which now contributes 22% of consolidated sales. The company holds the #1 market position in India with an 8.4% market share. The US business, while facing generic pricing pressures, saw its Innovative Medicines portfolio become a larger contributor to US revenues than its generics for the first time.
What changes now
The acquisition of Organon & Co. is expected to add Women’s Health as a new therapeutic pillar and expand participation in the biosimilars market. Kirti Ganorkar has assumed the role of Managing Director, with Dilip Shanghvi continuing as Executive Chairman, ensuring leadership continuity. The company also reported meeting 52.6% of its energy requirements through renewable sources.
Risks to watch
Sun Pharma faces ongoing regulatory scrutiny in the US, with certain manufacturing facilities classified as 'Official Action Indicated' (OAI) by the US FDA. Structural pricing pressures and compliance constraints in the US market remain a concern. Geopolitical risks, including trade policy uncertainties and supply chain disruptions, could also impact market dynamics.
Peer comparison
Sun Pharma maintains its leadership in the Indian market, with formulation sales growing 14% to ₹19,300 crore. Its US business saw a slight decline of 0.9% in formulation sales to US$1.904 million, largely due to generic pricing pressures, though innovative medicines showed resilience.
Context metrics (time-bound)
- Consolidated Revenue (FY26): ₹ 58,462 crore (up 11.9%)
- Consolidated Net Profit (FY26): ₹ 11,479 crore
- R&D Expenditure (FY26): ₹ 3,554 crore (6.1% of sales)
- India Formulation Sales (FY26): ₹ 19,300 crore (up 14%)
- US Formulation Sales (FY26): US$ 1,904 million (down 0.9%)
- Emerging Markets Sales (FY26): US$ 1,265 million (up 13.6%)
- Rest of World Sales (FY26): US$ 969 million (up 14.4%)
What to track next
Investors should closely monitor the progress and integration of the Organon & Co. acquisition. Remediation efforts at US manufacturing facilities to address regulatory concerns and the performance of the product launch pipeline will be key indicators. The continued growth of the innovative medicines portfolio and performance in emerging markets will also be important to watch.